YEISELL DUCONGE MUNARRIZ: Open Payments
NPI 1346744166 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$785 in 33 payments from 10 companies in 2025. Trend: 2023 $889 · 2024 $833 · 2025 $785
Food & beverage: $785
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $205 |
| Lundbeck LLC | 6 | $142 |
| Janssen Pharmaceuticals, Inc | 5 | $121 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $75 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Neos Therapeutics, LP | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
Products named: REXULTI, INVEGA SUSTENNA, Auvelity, CAPLYTA, FANAPT, AUSTEDO XR, COBENFY, Adzenys XR-ODT.
Industry payments across FL — which companies pay providers there.
